Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H20ClN5O3 |
| Molecular Weight | 377.825 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1C[C@H]2C[C@H](CC[C@H]2CN1)OC3=C(C4=NN=NN4)C(Cl)=CC=C3
InChI
InChIKey=LAKQPSQCICNZII-NOHGZBONSA-N
InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1
| Molecular Formula | C17H20ClN5O3 |
| Molecular Weight | 377.825 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:05:16 GMT 2025
by
admin
on
Mon Mar 31 20:05:16 GMT 2025
|
| Record UNII |
1P85D6BE9K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DASOLAMPANEL
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
51049972
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
XX-76
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
300000037044
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
9436
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
C166510
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
503294-13-1
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
1P85D6BE9K
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
DTXSID401032046
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103869
Created by
admin on Mon Mar 31 20:05:16 GMT 2025 , Edited by admin on Mon Mar 31 20:05:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
